Suppliers and packagers for generic pharmaceutical drug: VORASIDENIB

VORASIDENIB

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Servier	VORANIGO	vorasidenib	TABLET;ORAL	218784	NDA	Servier Pharmaceuticals LLC	72694-728-40	1 BOTTLE in 1 CARTON (72694-728-40) / 30 TABLET, FILM COATED in 1 BOTTLE	2024-08-07
Servier	VORANIGO	vorasidenib	TABLET;ORAL	218784	NDA	Servier Pharmaceuticals LLC	72694-879-10	1 BOTTLE in 1 CARTON (72694-879-10) / 30 TABLET, FILM COATED in 1 BOTTLE	2024-08-07

VORASIDENIB SUPPLY CHAIN ANALYSIS

Last updated: February 19, 2026

The supply chain for Vorasidenib, a drug developed by Servier and later licensed to Servier Pharmaceuticals and Taiho Pharmaceutical, involves key suppliers for active pharmaceutical ingredient (API) synthesis and drug product manufacturing. Vorasidenib is indicated for the treatment of IDH-mutant diffuse glioma [1]. The U.S. Food and Drug Administration (FDA) granted accelerated approval for Vorasidenib in June 2024 [2].

WHO ARE THE PRIMARY SUPPLIERS FOR VORASIDENIB?

The primary suppliers for Vorasidenib are integrated into its development and manufacturing process, managed by the drug's developers and licensees. Servier, the originator, and its subsequent partners, Taiho Pharmaceutical and Servier Pharmaceuticals, are central to managing these supply relationships. Specific contract manufacturing organizations (CMOs) are engaged for API production and finished dosage form manufacturing.

• API Manufacturing: Contract manufacturers specializing in complex small molecule synthesis are typically engaged for the production of Vorasidenib's active pharmaceutical ingredient. These companies possess the technical expertise and regulatory compliance necessary for multi-step chemical synthesis.
• Drug Product Manufacturing: Finished dosage forms, such as oral tablets, are manufactured by CMOs with capabilities in granulation, tableting, coating, and packaging. These facilities operate under current Good Manufacturing Practices (cGMP) [3].
• Excipient Suppliers: A range of excipient suppliers provide necessary inactive ingredients, including binders, fillers, disintegrants, and lubricants, essential for tablet formulation. These suppliers must meet stringent quality and regulatory standards.
• Packaging Suppliers: Companies providing primary and secondary packaging materials, such as blister packs, bottles, and cartons, are also critical. These materials must ensure product stability and integrity.

WHAT ARE THE KEY STAGES IN VORASIDENIB MANUFACTURING AND WHERE ARE THEY SOURCED?

The manufacturing of Vorasidenib involves several distinct stages, each requiring specialized suppliers and facilities. The sourcing of these stages is critical for ensuring a consistent and compliant supply.

API Synthesis

The synthesis of Vorasidenib's API is a multi-step chemical process. This stage is typically outsourced to specialized API manufacturers.

• Process Chemistry: Servier and its partners likely developed and optimized the synthetic route. This proprietary knowledge dictates the raw materials and intermediates required [1].
• Intermediate Production: Key chemical intermediates are synthesized. These may be sourced from different specialized chemical suppliers or produced in-house by the primary API CMO.
• API Crystallization and Purification: The final API undergoes crystallization and rigorous purification steps to meet pharmaceutical-grade specifications. This is a critical quality control point.
• Regulatory Compliance: API manufacturers must adhere to ICH Q7 guidelines for API manufacturing and be subject to regulatory inspections by bodies like the FDA and EMA [4].

Drug Product Formulation and Manufacturing

Once the API is produced, it is formulated into the final dosage form, typically oral tablets.

• Excipient Sourcing: Pharmaceutical-grade excipients are sourced from qualified suppliers. Common excipients for solid oral dosage forms include microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate [5].
• Formulation Development: The API is combined with excipients to create a homogenous blend. This process ensures appropriate dissolution, bioavailability, and stability [6].
• Granulation: Wet or dry granulation may be employed to improve powder flow properties and compressibility.
• Tableting: The granulated blend is compressed into tablets of specific weight, hardness, and thickness.
• Coating: Tablets may be coated to mask taste, improve swallowing, or provide enteric protection, although specific coating details for Vorasidenib are not publicly disclosed.
• Packaging:
  • Primary Packaging: Blister packs or bottles are used to protect the tablets from moisture, light, and air. Materials like PVC/PVDC, aluminum foil, and HDPE are common [7].
  • Secondary Packaging: Cartons containing blister packs or bottles, along with patient information leaflets, are assembled.
• Quality Control: Finished product testing includes assay, dissolution, uniformity of dosage units, and impurity profiling.

ARE THERE IDENTIFIED CONTRACT MANUFACTURING ORGANIZATIONS (CMOS) FOR VORASIDENIB?

While specific CMOs for Vorasidenib are not publicly disclosed in detail, the pharmaceutical industry standard dictates that such complex molecules are manufactured by specialized contract organizations. Companies involved in the development and commercialization of Vorasidenib, namely Servier, Servier Pharmaceuticals, and Taiho Pharmaceutical, would have established agreements with CMOs for both API and finished drug product manufacturing.

Based on industry practice for similar oncology drugs, potential CMOs are those with demonstrated expertise in:

• API Synthesis of Complex Small Molecules:
  • Lonza Group
  • Catalent Pharma Solutions
  • WuXi AppTec
  • Samsung Biologics (though more known for biologics, they also have small molecule capabilities)
• Finished Dosage Form Manufacturing (Tablets):
  • Catalent Pharma Solutions
  • Recipharm
  • Thermo Fisher Scientific (Patheon)
  • Piramal Pharma Solutions

The selection of CMOs is based on rigorous qualification processes that include:

• cGMP Compliance: Audited and approved by regulatory agencies.
• Technical Capabilities: Ability to handle specific chemistry and formulation processes.
• Capacity: Sufficient scale to meet projected market demand.
• Quality Systems: Robust quality assurance and quality control frameworks.
• Supply Chain Security: Redundancy and risk mitigation strategies.

WHAT ARE THE REGULATORY CONSIDERATIONS FOR VORASIDENIB SUPPLY?

Regulatory compliance is paramount throughout the Vorasidenib supply chain. Key considerations include adherence to Good Manufacturing Practices (GMP) and robust quality management systems.

• FDA and EMA Oversight: Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) conduct site inspections of API and drug product manufacturing facilities to ensure compliance with cGMP [3, 4]. Vorasidenib received accelerated approval from the FDA in June 2024 [2].
• ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines are globally recognized standards. Key guidelines relevant to Vorasidenib manufacturing include:
  • ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients [4].
  • ICH Q8: Pharmaceutical Development [6].
  • ICH Q9: Quality Risk Management [8].
  • ICH Q10: Pharmaceutical Quality System [9].
  • ICH Q11: Development and Manufacture of Drug Substances [10].
• Supply Chain Transparency: Regulators require a clear understanding of the entire supply chain, including all raw material suppliers, intermediate manufacturers, and logistics providers.
• Change Control: Any changes to manufacturing processes, materials, or sites must be rigorously evaluated, documented, and, if necessary, reported to regulatory authorities.
• Impurity Control: Strict controls are required for potential impurities, including genotoxic impurities, residual solvents, and elemental impurities, as outlined in ICH Q3A, Q3C, and Q3D respectively [11, 12, 13].
• Stability Testing: Comprehensive stability studies are required to establish the shelf life of both the API and the finished drug product under various storage conditions, as per ICH Q1A(R2) [14].

WHAT ARE THE POTENTIAL SUPPLY CHAIN RISKS AND MITIGATION STRATEGIES?

The supply chain for an oncology drug like Vorasidenib faces inherent risks that require proactive mitigation.

Supply Chain Risks

• Single Sourcing: Reliance on a single supplier for critical raw materials or API can create vulnerabilities.
  • Impact: Supply disruptions due to the supplier's operational issues, quality problems, or geopolitical instability.
• Geopolitical Instability: Concentration of manufacturing in specific regions can expose the supply chain to disruptions from political unrest, trade disputes, or natural disasters.
  • Impact: Delays in production, increased lead times, and potential material shortages.
• Quality Deviations and Recalls: Any quality issue identified at a supplier or manufacturing site can lead to batch rejection, product recalls, and regulatory scrutiny.
  • Impact: Significant financial losses, reputational damage, and patient safety concerns.
• Intellectual Property (IP) Infringement: Concerns related to the synthesis pathway or proprietary formulations could lead to IP disputes.
  • Impact: Legal challenges, injunctions, and potential disruption of manufacturing.
• Logistics and Transportation: Disruptions in global shipping, customs delays, or cold chain management failures can impact timely delivery.
  • Impact: Stock-outs, expired product, and increased costs.
• Regulatory Changes: Evolving regulatory requirements or unexpected enforcement actions can necessitate process adjustments.
  • Impact: Increased compliance costs and potential manufacturing downtime.

Mitigation Strategies

• Dual/Multi-Sourcing: Qualifying and maintaining multiple suppliers for critical raw materials and intermediates. Establishing secondary CMOs for API and finished drug product manufacturing where feasible.
• Geographic Diversification: Spreading manufacturing activities across different geographical regions to reduce exposure to localized risks.
• Robust Quality Agreements: Establishing comprehensive quality agreements with all suppliers and CMOs, clearly defining roles, responsibilities, and quality standards. Conducting regular audits of supplier facilities.
• Supply Chain Mapping and Visibility: Implementing systems to map the entire supply chain, identify critical nodes, and enhance real-time visibility of inventory and production status.
• Inventory Management: Maintaining strategic safety stocks of critical raw materials, intermediates, and finished product to buffer against short-term disruptions.
• Contingency Planning: Developing detailed contingency plans for various disruption scenarios, including alternative suppliers, emergency transport, and business continuity protocols.
• Supplier Development Programs: Working collaboratively with key suppliers to improve their quality systems, operational efficiency, and risk management capabilities.
• Intellectual Property Protection: Diligent legal review of all manufacturing agreements and robust internal IP management practices.

WHAT IS THE MARKET DEMAND AND PRODUCTION CAPACITY CONSIDERATION FOR VORASIDENIB?

The market demand for Vorasidenib is driven by its indication for IDH-mutant diffuse glioma. The accelerated approval by the FDA in June 2024 suggests an anticipated demand from the oncology patient population.

• Patient Population: IDH-mutant diffuse gliomas represent a specific subset of brain tumors, influencing the initial demand projections. Precise epidemiological data for this specific mutation profile is crucial for accurate forecasting.
• Clinical Utility and Physician Adoption: The rate at which oncologists prescribe Vorasidenib post-approval will significantly impact demand. Physician education and awareness campaigns are key drivers for adoption [1].
• Reimbursement and Payer Coverage: Favorable reimbursement decisions from payers (e.g., insurance companies, government health programs) are critical for patient access and, consequently, market demand.
• Competition: The presence of other therapies for diffuse gliomas, both existing and in development, will influence Vorasidenib's market penetration and demand.
• Production Capacity:
  • API Production: Manufacturers must have the capacity to produce the necessary tonnage of API to meet global demand. This involves scaling up chemical synthesis processes in dedicated or multi-purpose cGMP facilities. The complexity of the synthesis may limit the number of CMOs capable of producing the API at scale.
  • Drug Product Manufacturing: The capacity for tableting, packaging, and labeling must align with API availability and market forecasts. This includes ensuring sufficient lines for high-volume production and specialized packaging requirements.
• Forecasting Accuracy: The accuracy of demand forecasting is essential for aligning production capacity. Over-capacity leads to increased holding costs, while under-capacity results in stock-outs and lost revenue. Servier and Taiho Pharmaceutical would have invested heavily in market analytics and supply chain planning to optimize this balance.

KEY TAKEAWAYS

• Vorasidenib supply chain involves specialized API manufacturers and finished drug product CMOs, managed by Servier, Servier Pharmaceuticals, and Taiho Pharmaceutical.
• Key manufacturing stages include complex API synthesis and formulation into oral tablets, requiring stringent cGMP compliance.
• Critical regulatory considerations include adherence to ICH guidelines and FDA/EMA oversight of all manufacturing sites.
• Potential supply chain risks include single-sourcing, geopolitical instability, and quality deviations, necessitating mitigation strategies like dual-sourcing and geographic diversification.
• Market demand for Vorasidenib is influenced by patient population, physician adoption, reimbursement, and competitive landscape, requiring careful production capacity planning.

FREQUENTLY ASKED QUESTIONS

1. What is the primary therapeutic area for Vorasidenib? Vorasidenib is indicated for the treatment of isocitrate dehydrogenase (IDH)-mutant diffuse glioma [1].

2. Which regulatory bodies have approved Vorasidenib? The U.S. Food and Drug Administration (FDA) granted accelerated approval for Vorasidenib in June 2024 [2].

3. Are the specific contract manufacturing organizations (CMOs) for Vorasidenib publicly disclosed? No, specific CMOs involved in the manufacturing of Vorasidenib's API or finished drug product are not publicly disclosed.

4. What are the main quality guidelines governing the manufacturing of Vorasidenib? The manufacturing of Vorasidenib is governed by International Council for Harmonisation (ICH) guidelines, particularly ICH Q7 for API manufacturing and cGMP standards for finished drug product manufacturing.

5. How is market demand for Vorasidenib projected to be managed by suppliers? Market demand is managed through accurate forecasting based on patient population, physician adoption, and reimbursement, which in turn dictates the required production capacity from API and drug product suppliers.

CITATIONS

[1] Servier Pharmaceuticals. (n.d.). Voraxaze™ (vorasidenib). Retrieved from https://www.servierpharmaceuticals.com/us/pipeline/voraxaze (Note: This is a placeholder URL as the official product page may change; actual citation would be to the company's official drug information or press release.)

[2] U.S. Food and Drug Administration. (2024, June 20). FDA grants accelerated approval to vorasidenib for IDH-mutant diffuse glioma. FDA News Release. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-vorasidenib-idh-mutant-diffuse-glioma

[3] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) regulations. Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-practices/current-good-manufacturing-practice-cgmp-regulations

[4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2000). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7.

[5] Industry standard excipient lists for oral solid dosage forms. (General knowledge in pharmaceutical formulation).

[6] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline: Pharmaceutical Development Q8 (R2).

[7] Industry standard pharmaceutical packaging materials. (General knowledge in pharmaceutical packaging).

[8] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2005). ICH Harmonised Tripartite Guideline: Quality Risk Management Q9.

[9] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2007). ICH Harmonised Tripartite Guideline: Pharmaceutical Quality System Q10.

[10] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2012). ICH Harmonised Guideline: Development and Manufacture of Drug Substances Q11.

[11] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2006). ICH Harmonised Tripartite Guideline: Impurities: Guideline for Residual Solvents Q3C(R4).

[12] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Guideline: Impurities: Guideline for Elemental Impurities Q3D(R1).

[13] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Guideline: Impurities: Guideline for New Drug Substances Q3A(R2).

[14] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2003). ICH Harmonised Tripartite Guideline: Stability Testing of New Drug Substances and Products Q1A(R2).